PDGFRA and PDGFRB were targeted by multiple drugs, and imatinib, a BCR-ABL inhibitor [13], was identified to target both PDGFRA and PDGFRB in S:E fusion-positive prostate cancer. Here, PDGFRA is linked to prostate carcinoma.